KB Home (NYSE:KBH) reported third-quarter fiscal 2026 results that met or exceeded its guidance despite what executives described as a more difficult housing environment marked by rising mortgage rates, affordability pressures, higher resale inventory and cautious consumers.
The homebuilder generat
Fastly (NASDAQ:FSLY) outlined a strategy centered on expanding its unified edge cloud platform, increasing multi-product adoption, broadening its geographic reach and targeting revenue of $1.1 billion to $1.3 billion by 2029 at its Investor Day.
Chief Executive Officer Kip Compton said the company
Corporate Procurement Strategies: Streamlining Physical Workspaces to Drive Operational ROIIn an era dominated by digital transformation, physical workspac
Bruno Morand De Oliveira's purchase brings his direct holdings to over 1 million shares, following a 44% one-year gain for the offshore drilling contractor.
Abeona Therapeutics (NASDAQ:ABEO) highlighted the early commercial progress of ZEVASKYN, its autologous gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the H.C. Wainwright 28th Annual conference.
Madhav Vasanthavada, Abeona’s senior vice president
Peptide standards are the reference materials that make peptide analysis trustworthy. Whether a lab is validating an LC-MS method, checking assay performan
Bloom Energy chases AI-driven growth with mounting losses and debt, while NextEra Energy delivers stable profits backed by 6 million utility customers.
Lithium Americas is reaching a critical stage where construction progress could reshape the investment case. See what still has to go right before the market closes the gap.
VEA concentrates on established economies with lower costs and higher income, while VWO pursues growth in developing nations with greater tech exposure and volatility.
Alexandros Pappas expanded his indirect holdings by 74,400 shares through three controlled entities, signaling confidence as the stock surges 61% over one year.
Compass Pathways (NASDAQ:CMPS) said it remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter of 2026, following positive Phase III studies of its synthetic psilocybin treatment in treatment-resistant depression, or TRD.
During H.C. Wainwright’s G
Bloom Energy is profitable on a free cash flow basis, while Eos Energy Enterprises is burning cash despite explosive revenue growth, a critical divide for risk-conscious investors.
Vanguard's 0.06% expense ratio and emerging-market exposure outpace iShares' developed-markets-only approach, though performance diverges less than fees suggest.
